Not known Factual Statements About ABBV-744 preclinical studies and results
In Phase C, members will receive ABBV-744 and oral navitoclax. In Section D, participants will obtain ABBV-744 and ruxolitinib. Contributors will get treatment right until ailment progression or the individuals are unable to tolerate the study drugs.For all movement cytometry experiments, ten,000 cells per replicate were being analyzed, and 3 repli